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Background: The t(1;19)(q23;p13), which can result in the TCF3-PBX1 chimeric gene, is one of the most frequent
translocations in B-acute lymphoblastic leukemia (B-ALL) and is observed in both adult and pediatric populations at
an overall frequency of 6%. It can occur in a balanced or unbalanced form and as a sole abnormality is associated
with an intermediate prognosis. Additionally, this translocation is observed in the context of hyperdiploid B-ALL,
in which case it is associated with a poor prognosis. However, due to different translocation partner genes at
chromosomes 1 and 19, distinct subtypes of hyperdiploid B-ALL with t(1;19)/der(19)t(1;19) are recognized based on
the presence or absence of the TCF3-PBX1 fusion gene, but the cytogenetic and etiologic differences between the
two remain understudied.
Findings: We report a case of an adult with a history of relapsed precursor B-ALL whose conventional cytogenetics
showed an abnormal female karyotype with both hyperdiploidy and a t(1;19)(q23;p13). Fluorescence in situ hybridization
(FISH) on previously G-banded metaphases using the LSI TCF3/PBX1 Dual Color, Dual Fusion Translocation Probe
confirmed the presence of the TCF3-PBX1 gene fusion.
Conclusions: This particular pattern with a TCF3-PBX1 fusion within the context of a hyperdiploid karyotype is seen in
B-ALL and is usually associated with a poor outcome. This case is one of only a few cases with both hyperdiploidy and
a confirmed TCF3-PBX1 fusion, demonstrating the importance of using FISH for proper molecular classification of these
cases in order to distinguish them from those with hyperdiploidy but no TCF3-PBX1 fusion gene. Such molecular
studies may provide insight into the precise differences between TCF3-PBX1 positive and negative hyperdiploid B-ALL
bearing the t(1;19)(q23;p13).
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The t(1;19)(q23;p13) is one of the most frequent translo-
cations in B-acute lymphoblastic leukemia (B-ALL), and
is observed in both adult and pediatric populations at an
overall frequency of 6% . This translocation can occur in
a balanced – t (1;19)(q23;p13) – or unbalanced – der
(19)t(1;19)(q23;p13) – form and can result in the fusion
of TCF3 (transcription factor 3) found at 19p13 and* Correspondence: ctirado@mednet.ucla.edu
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unless otherwise stated.PBX1 (pre-B cell leukemia homebox 1) found at 1q23 to
form a chimeric gene whose protein product alters cell
differentiation arrest, among other cellular processes [1].
Specifically, the fusion gene encodes a transcription
factor bearing the transactivation domain of TCF3 and
the DNA-binding domain of PBX1, which facilitates
constitutive activation of genes bound by the protein
encoded by PBX1 and other PBX proteins [2]. As a sole
abnormality, t(1;19)/der(19)t(1;19) is associated with an
intermediate prognosis in B-ALL, and hyperdiploidy is
associated with a favorable prognosis [1]. However, more
rarely, cases of t(1;19)/der(19)t(1;19) within the contextThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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some of which express the TCF3-PBX1 fusion gene and
are associated with a poor prognosis [3]. In addition to
PBX1, other partner genes involved in rearrangements of
TCF3, although at much lower frequencies, include
ZNF384 (12p13; prognosis unknown), NOL1 (12p13;
prognosis unknown), an unknown partner gene at 13q14
(prognosis unknown), HLF (17q22; extremely poor prog-
nosis), and FB1/TFPT (19q13.4; prognosis unknown)
[4-6]. The cytogenetic and etiologic differences between
TCF3-PBX1 positive and negative B-ALL with hyperdi-
ploidy and t(1;19)/der(19)t(1;19) remain understudied
due to lack of molecular classification of the cases
reported in the literature.
Case presentation
The patient was a forty-four year old woman with a
history of relapsed precursor B-ALL, who was initially
diagnosed in March 2013 with leukemic cells showing
an immunophenotype positive for CD10, CD19, icCD22,
CD38, icCD79a, CD138, TdT, HLA-DR and icIgM as
well as a normal karyotype. Initial diagnosis was estab-
lished at another institution at which point FISH
analysis was not performed. After UK ALL 14 protocol
consolidation therapy, she was considered to be in
remission. In December 2013, a bone marrow biopsy
showed evidence of relapse, and was comprised of
approximately 85% blasts with a pre-B immunopheno-
type and a hyperdiploid, complex, poor-risk karyotype,
further described in the results section. In January
2014, the patient underwent therapy with FLAG-Ida,
resulting in a hypoplastic marrow with no significant
residual blast population. Later in April 2014 she
enrolled in a clinical trial with blinatumomab, which
was eventually discontinued because the patient experi-
enced multiple seizure episodes. A bone marrow biopsy
showed extensive tumor necrosis with involvement by
B-lymphoblasts representing over 90% of viable cells
and comprising 5% of the total surface area. The immu-
nophenotype was positive for CD10, CD19, PAX-5,
CD79a and TdT (weak, rare), and negative for CD34
and CD20. The patient expired in May 2014 of relapsed
B-lymphoblastic leukemia. Autopsy included a bone
marrow biopsy, which revealed a hypercellular marrow
of greater than 95% cellularity with sheets of lympho-
blasts and extensive tumor necrosis.
Material and methods
Chromosome analysis was performed using standard
cytogenetic techniques on the bone marrow of this
patient. The karyotypes were prepared using the Applied
Imaging CytoVision software (Applied Imaging, Genetix,
Santa Clara, CA) and described according to the ISCN
2013 nomenclature [7].Fluorescence in situ hybridization (FISH) was performed
on interphase nuclei using the Vysis MYC-IGH Dual
Color, Dual Fusion Probe, Vysis LSI BCR,ABL ES Dual
Color Translocation Probe, and Vysis LSI MLL Dual
Color, Break Apart Rearrangement Probe from Abbott
Molecular (Des Plaines, Illinois 60018). Additionally, FISH
was performed with the LSI TCF3/PBX1 Dual Color,
Dual Fusion Translocation Probe on previously G-banded
metaphases.
Findings
Only three metaphase cells were available for chromo-
some analysis due to a poor mitotic index. These cells
revealed an abnormal female karyotype with numerical
and structural abnormalities including extra copies of
chromosomes 1, 8, 11, 20, 22, a (1;19) translocation, an
unbalanced rearrangement of the long arm of chromosome
13 leading to 13q-, and a marker chromosome of unknown
origin. This karyotype was described as (Figure 1):
53–54;XX;þ1; t 1; 19ð Þ q23; p13ð Þ;þ8;þ8;þ8;þ11;
add 13ð Þ q34ð Þ;þ20;þ22;þmar cp3½ 
FISH on interphase nuclei confirmed the additional
copies of chromosome 8 in 73.8% of nuclei (79/107),
chromosome 22 in 80% of nuclei (44/55), as well as
chromosome 11 in 4.7% of nuclei (4/85) examined. The




To further characterize and confirm the previous con-
ventional cytogenetics findings [t(1;19) which fuses TCF3
(green signal) on 19p13 with PBX1 (red signal) at 1q23],
FISH studies on previously G-banded metaphases were
performed, and detected two fusion [t(1;19)] signals and
an additional copy of red signal (+1q) with the TCF3-
PBX1 probe indicative of translocation between TCF3 and
PBX1, as well as an additional copy of the 1q23 locus,
which is consistent with the karyotype results found previ-
ously. Gain of chromosome 1q is often seen in association
with disease progression or advanced disease. Based on
these studies the karyotype was described as (Figure 3):
53‐54;XX;þ1; t 1; 19ð Þ q23; p13ð Þ;þ8;þ8;þ8;þ11;
add 13ð Þ q34ð Þ;þ20;þ22;þmar cp3½ :ish PBX1x4ð Þ
TCF3x3ð Þ PBX1 con TCF3x2ð Þ
Discussion
The t(1;19)(q23;p13)/der(19)t(1;19)(q23;p13) is one of
the most common translocations seen in B-ALL cases
Figure 1 Karyotype of female patient revealing t(1;19) in a hyperdiploid context.
Figure 2 FISH analysis was used to confirm the additional
copies of chromosomes 8, 22 and 11.
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fusion of TCF3 on 19p13 with PBX1 at 1q23, can be
present in balanced or unbalanced form, and is usually
associated with an intermediate prognosis [1]. Hunger
et al. noted in an early study that 95% of t(1;19)/der(19)t
(1;19)-positive cases of B-ALL with <50 chromosomes
expressed the TCF3-PBX1 fusion transcript, whereas
only 25% of cases with >50 chromosomes did. Further-
more, immunophenotypic differences between TCF3-PBX1
positive and TCF3-PBX1 negative cases were observed,
which suggested etiologic differences between the two
subtypes [3].
In a recent study conducted by Paulsson et al., 42 cases
with both t(1;19)/der(19)t(1;19) and high hyperdiploidy
(HeH; 51–67 chromosomes) from both published literature
and the LRCG database were analyzed, revealing similar
numerical chromosomal gains in both translocation-HeH
(t-HeH) and classic-HeH (c-HeH) cases, most commonly
involving chromosomes 21, 4, 6, 10, 18, 14, X, and 17, in
decreasing frequency [8]. Furthermore, none of these cases
were found to have a stemline balanced or unbalanced t
(1;19), whereas 11% had hyperdiploid stemlines, suggesting
that numerical chromosomal gains resulting in HeH are
primary cytogenetic aberrations and occur prior to t(1;19)/
der(19)t(1;19) [8]. This may result in clinical similarities
between t(1;19)/der(19)t(1;19)-HeH ALL and c-HeH ALL,
as the two may share a similar cytogenetic progression and
Figure 3 FISH on a previously G-banded metaphase confirmed t(1;19)(q23;p13) involving the TCF3 and PBX1 genes, as well as an
additional copy of chromosome 1.
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(19)t(1;19)-HeH cases tested by molecular methods were
negative for the presence of the TCF3-PBX1 fusion gene
[8]. Additionally, previous studies have found that greater
than 90% of t(1;19) positive, TCF3-PBX1 fusion negative
cases have an unbalanced form of the rearrangement [4]. In
Paulsson et al’s study, only 18% of the cases had a balanced
rearrangement [8], while 40% of TCF3-PBX1 positive cases
overall have been found to have a balanced rearrangement
[1], ultimately suggesting etiologically distinct subtypes of
B-ALL with both hyperdiploidy and t(1;19)/der(19)t(1;19)Table 1 Cases of adult B-ALL with hyperdiploidy, t(1;19)/der(1










Prognostic data were limited for these cases.
*Reference does not provide further clinical/prognostic data about the malignancy.
**Reference indicates that disease did not relapse.
***Reference indicates that disease relapsed.based on the presence of the TCF3-PBX1 fusion gene by
FISH and/or polymerase chain reaction (PCR) [8].
In the present study, we report a case of hyperdiploid
B-ALL with a balanced t(1;19) bearing the TCF3-PBX1
fusion gene confirmed by metaphase FISH, which has
only been previously reported in a small number of cases
and represents a distinct subtype of B-ALL based on the
presence of the confirmed fusion gene in conjunction
with hyperdiploidy and t(1;19)/der(19)t(1;19). Interestingly,
the numerical gains present in our case, of chromosomes







20,+22,+mar[cp3].ish(PBX1x4)(TCF3x3)(PBX1 con TCF3 x2) This report
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Paulsson et al. [8]. In that study, the majority of cases were
found to have unbalanced rearrangements and out of
those that had molecular evidence, most did not bear the
TCF3-PBX1 fusion [8]. The presence of different numer-
ical gains between our case and those of Paulsson et al.
further supports the fact that the TCF3-PBX1 positive and
negative variants of t(1;19)/hyperdiploid B-ALL represent
distinct subtypes of the disease. Furthermore, we queried
the Mitelman Database of Chromosome Aberrations in
Cancer for reported cases of ALL with t(1;19)/der(19)t
(1;19), hyperdiploidy, and molecular evidence (FISH and/
or PCR) of TCF3-PBX1 fusion, and only identified 5 cases
that were positive for the fusion (Table 1). When compil-
ing the karyotypes of these cases and the present case, we
noted that four out of six cases had additional copies of
chromosome 8, which was interestingly not found to be
one of the most common numerical gains in t-HeH/t
(1;19)-positive B-ALL [8].
Recent molecular insights into the TCF3-PBX1 fusion
protein have revealed its involvement in complex signaling
pathways. In particular, deregulation of JunD and NFX1-
regulated transcriptional processes has been noted to be a
significant effect of the fusion protein [9]. Additionally,
PAX5 (19p13.2) haploinsufficiency, detectable both by
conventional and molecular cytogenetics, is associated
with TCF3-PBX1 in B-ALL. Specifically, FISH using both
TCF3 split signal probes in conjunction with PAX5 locus-
specific deletion probes suggests that PAX5 is a secondary
event in the oncogenesis of TCF3-PBX1-positive B-ALL,
and may be associated with clonal evolution of the
malignancy [10]. Furthermore, studies have revealed that
vascular endothelial growth factor-C (VEGF-C), encoded
by VEGFC (4q34.3), is involved and perhaps essential to
proliferation of TCF3-PBX1 positive leukemic B cells [11].
Finally, treatment with hyperfractionated cyclophos-
phamide, vincristine, doxorubicin, and dexamethasone
alternating with methotrexate and high-dose cytarabine
(hyper-CVAD) has shown a favorable outcome in adults
with t(1;19)-positive ALL [12].
Hyperdiploidy in B-ALL normally conveys a favorable
prognosis, but in the present study, the particular pattern
of a t(1;19)(q23;p13.3) with TCF3-PBX1 fusion within the
context of a complex karyotype (>3 abnormalities) and
hyperdiploidy due to extra copies of chromosomes 8, 11
and 22 (confirmed by FISH) plus the presence of a marker
chromosome of unknown origin is associated with an
unfavorable prognosis in B-ALL [3]. It is one of only a few
published cases with hyperdiploidy, t(1;19)/der(19)t(1;19),
and a confirmed TCF3-PBX1 fusion in B-ALL, demon-
strating the importance of using FISH and PCR for proper
cytogenetic and molecular classification in order to distin-
guish the present scenario from hyperdiploid B-ALL with
t(1;19)/der(19)t(1;19), but lacking the TCF3-PBX1 fusion.The latter represents a different subtype of B-ALL that
may be primarily driven by chromosomal gains or other
fusion genes rather than the t(1;19)/der(19)t(1;19) result-
ing in the TCF3-PBX1 fusion and should not be confused
with the entity presented in this report. Further investiga-
tion of the cytogenetic and molecular etiologies of these
subtypes of B-ALL is warranted to determine their impli-
cations in the diagnosis and prognosis of the malignancy.
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